Page last updated: 2024-08-17

bromoethane and levofloxacin

bromoethane has been researched along with levofloxacin in 2 studies

Research

Studies (2)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	2 (100.00)	29.6817
2010's	0 (0.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Bonventre, EJ; Doyle, TB; Du, Q; Duncan, L; Lynch, AS; Morris, TW; Robertson, GT; Roche, ED; Yan, D	1
Bohnert, JA; Fähnrich, E; Kern, WV; Schuster, S; Wehmeier, C	1

Other Studies

2 other study(ies) available for bromoethane and levofloxacin

Article	Year
In vitro evaluation of CBR-2092, a novel rifamycin-quinolone hybrid antibiotic: studies of the mode of action in Staphylococcus aureus. Antimicrobial agents and chemotherapy, 2008, Volume: 52, Issue:7 Topics: Anti-Bacterial Agents; Bacterial Proteins; DNA Topoisomerase IV; DNA-Directed RNA Polymerases; DNA, Bacterial; Drug Resistance, Bacterial; Enzyme Inhibitors; Microbial Sensitivity Tests; Molecular Structure; Mutation; Quinolones; Rifamycins; RNA, Bacterial; Staphylococcus aureus; Topoisomerase II Inhibitors	2008
Site-directed mutagenesis reveals amino acid residues in the Escherichia coli RND efflux pump AcrB that confer macrolide resistance. Antimicrobial agents and chemotherapy, 2009, Volume: 53, Issue:1 Topics: Amino Acid Sequence; Anti-Bacterial Agents; Drug Resistance, Bacterial; Escherichia coli; Escherichia coli Proteins; Macrolides; Molecular Sequence Data; Multidrug Resistance-Associated Proteins; Mutagenesis, Site-Directed; Sequence Homology, Amino Acid	2009

Article

Year

In vitro evaluation of CBR-2092, a novel rifamycin-quinolone hybrid antibiotic: studies of the mode of action in Staphylococcus aureus.

Antimicrobial agents and chemotherapy, 2008, Volume: 52, Issue:7

Topics: Anti-Bacterial Agents; Bacterial Proteins; DNA Topoisomerase IV; DNA-Directed RNA Polymerases; DNA, Bacterial; Drug Resistance, Bacterial; Enzyme Inhibitors; Microbial Sensitivity Tests; Molecular Structure; Mutation; Quinolones; Rifamycins; RNA, Bacterial; Staphylococcus aureus; Topoisomerase II Inhibitors

2008

Site-directed mutagenesis reveals amino acid residues in the Escherichia coli RND efflux pump AcrB that confer macrolide resistance.

Antimicrobial agents and chemotherapy, 2009, Volume: 53, Issue:1

Topics: Amino Acid Sequence; Anti-Bacterial Agents; Drug Resistance, Bacterial; Escherichia coli; Escherichia coli Proteins; Macrolides; Molecular Sequence Data; Multidrug Resistance-Associated Proteins; Mutagenesis, Site-Directed; Sequence Homology, Amino Acid

2009